![]() ![]() From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Over the years it has been remarkably consistent. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.Īnd this outperformance has not just been a recent phenomenon. It's hard to believe, even for us at Zacks. Today's Stocks from Zacks' Hottest Strategies Surmodics’ long-term earnings growth rate is estimated at 10%. OPKO Health’s long-term earnings growth rate is projected at 12%. You can see the complete list of today’s Zacks #1 Rank stocks here. Integer Holdings has an earnings growth rate of 31.2% for the next quarter and a Zacks Rank #2. ( OPK Quick Quote OPK - Free Report) and Surmodics ( SRDX Quick Quote SRDX - Free Report). Some better-ranked stocks in the broader medical space are Integer Holdings Corporation ( ITGR Quick Quote ITGR - Free Report), OPKO Health, Inc. Our research shows that stocks with a Growth Score of A or B, when combined with a Zacks Rank #1 (Strong Buy) or 2 (Buy) are better picks than most. This reflects possibilities of outperformance over the long haul. The same for earnings stands at $4.69, showing growth of 6.1% year over year. The same for revenues is pinned at $714.3 million, showing an increase of 5.3% year over year.įor fiscal 2019, the Zacks Consensus Estimate for revenues is at $3.10 billion, reflecting a rise of 6.2% year over year. Quoteįor the fiscal first quarter, the Zacks Consensus Estimate for earnings is pegged at $1.06. Price and Consensus | Varian Medical Systems, Inc. (Read More: Varian & Reliance Group Tie Up to Enhance Cancer Care) (Read More: Varian Medical's Halcyon Gets NMPA Approval in China)Įarlier, Varian Medical’s Advanced Radiotherapy Clinical School started running courses at India-based Reliance Group's flagship Kokilaben Dhirubhai Ambani Hospital (KDAH) in Mumbai. Recently, Varian Medical’s coveted Halcyon system was approved by the China National Medical Product Administration (NMPA). Last month, Varian Medical announced that it was selected by Medical Specialist Holdings to equip seven of its centers in South Africa with Varian linear accelerators and Eclipse treatment planning system. The California-based provider of radiotherapy also enjoys a strong international presence. (Read More: Varian Acquires humediQ, Boosts Motion Management Portfolio) (Read More: Varian Buys Noona to Boost Oncology Software Services)Įarlier this year, Varian Medical extended its Oncology portfolio with the acquisition of humediQ, the manufacturer of IDENTIFY, a surface-guided radiation therapy positioning and motion management system. In October, the company bought Noona Healthcare, whose patient software app helps capture cancer patient-reported outcomes (PROs) and enable direct communication with patients. Varian Medical has lately been on an acquisition spree. Selling, general and administrative expenses also increased 4.1% year over year. Notably, Varian Medical’s research and development expenses rose 15.3% year over year to $59.6 million in the quarter. In fact, in the last reported quarter, the company’s gross margin was 42.3% of net revenues, down 10 basis points (bps) on a year-over-year basis. The current level is higher than the S&P 500 index’s 2.3% gain.Īn intensely competitive industry is likely to keep Varian Medical’s margins under pressure. Over the past year, shares of Varian Medical have rallied 8% compared with the industry’s 13.8% rise. The stock currently has a Zacks Rank #3 (Hold). However, the company’s margins are pressed. is expected to benefit from acquisitions and significant international presence. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |